Skip to main content

Table 2 Analysis for OS of total patients

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

  Univariate Multivariate
Variables Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age <40 0.86 (0.66–1.13) 0.29 - -
Post-menopausal state 1.11 (0.77–1.59) 0.59 - -
DFI* >2 yr 0.63 (0.48–0.83) 0.001 0.65 (0.48–0.86) 0.003
Initial stage IV 0.93 (0.67–1.29) 0.66 - -
ER**/PR*** positive 0.36 (0.27–0.48) < 0.001 0.41 (0.31–0.56) < 0.001
HER2 positive 1.50 (1.13–1.98) 0.005 0.94 (0.69–1.28) 0.69
Visceral metastasis 2.02 (1.55–2.65) < 0.001 1.93 (1.39–2.68) < 0.001
Sum of metastasis sites ≥ 3 1.53 (1.17–2.00) 0.002 0.99 (0.73–1.37) 0.96
BP use 0.52 (0.37–0.73) < 0.001 0.70 (0.50–0.98) 0.96
  1. Abbreviations: *, disease free interval; **, estrogen receptor; ***, progesteron receptor; †, bisphosphonate;.